Supernus Pharmaceuticals, Inc. - Common Stock (SUPN)
49.43
+0.00 (0.00%)
NASDAQ· Last Trade: May 18th, 6:04 AM EDT
Detailed Quote
Previous Close
49.43
Open
-
Bid
41.43
Ask
78.19
Day's Range
N/A - N/A
52 Week Range
30.83 - 59.68
Volume
1,077
Market Cap
2.63B
PE Ratio (TTM)
-72.69
EPS (TTM)
-0.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
747,359
Chart
About Supernus Pharmaceuticals, Inc. - Common Stock (SUPN)
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of central nervous system disorders, particularly epilepsy and attention deficit hyperactivity disorder (ADHD). The company leverages its proprietary drug formulation technologies to create specialized medications that enhance patient outcomes. With a commitment to addressing unmet medical needs, Supernus actively engages in research and development, aiming to expand its product offerings and provide effective treatment solutions for patients suffering from these challenging conditions. Read More
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...
Supernus Pharmaceuticals’ first quarter saw a positive market response, as management attributed the revenue growth to robust demand for its key growth produ...
What Happened? Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 6.8% in the afternoon session after the company repor...
ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas, NV.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 38.6% year on yea...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged...
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 38.6...
ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter 2026 and associated Company developments.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results this Tuesday after the bell. Here’s what to look ...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026.
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas...
Supernus Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 14.1%. The stock now trades at $53.23, m...
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 21.5% year on year to $211.6 million. On the other hand, the company’s full-year revenue guidance of $855 million at the midpoint came in 0.7% below analysts’ estimates. Its GAAP loss of $0.07 per share was 66.7% above analysts’ consensus estimates.
ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the fourth quarter and full year 2025 and associated Company developments.
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following March investor conferences:
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN)
will be announcing earnings results this Tuesday after market hours. Here’s what investors should know.
